Effects of short-acting NMDA receptor antagonist MRZ 2/576 on morphine tolerance development in mice.
The present study sought to evaluate the ability of a short-acting glycineB site NMDA receptor antagonist, MRZ 2/576, to affect morphine tolerance development in mice. It was found that MRZ 2/576 (10 mg/kg, i.p.) significantly retarded development of morphine analgesic tolerance (20 mg/kg, s.c., 8 days, once a day; tail-flick test) when administered 120 min or 150 min after each daily morphine injection. MRZ 2/576 did not affect the development of morphine tolerance when administered immediately, 15, 30, 60, 90, 180, 240, 300 or 360 min after the daily morphine injections. Thus, short-acting NMDA receptor antagonists may be useful in exploring the temporal characteristics of opioid tolerance (i.e., periods after morphine injection that are critical for tolerance induction) and the present study suggests that after morphine administration there is a period of NMDA receptors activation crucial for the development of tolerance.
Belozertseva
I V
IV
Laboratory of Behavioral Pharmacology, Institute of Pharmacology, Pavlov Medical University, St. Petersburg, Russia.
Danysz
W
W
Bespalov
A Y
AY
D000698:Analgesia; D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance; D006207:Half-Life; D008297:Male; D051379:Mice; D009020:Morphine / Q000494:pharmacology*; D010147:Pain Measurement; D010793:Phthalazines / Q000494:pharmacology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D013997:Time Factors
D000701:Analgesics, Opioid; C112266:MRZ 2-576; D010793:Phthalazines; D016194:Receptors, N-Methyl-D-Aspartate; D009020:Morphine